372 related articles for article (PubMed ID: 8561503)
1. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Ness GC; Zhao Z; Lopez D
Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
[TBL] [Abstract][Full Text] [Related]
2. Compensatory responses to inhibition of hepatic squalene synthase.
Lopez D; Chambers CM; Keller RK; Ness GC
Arch Biochem Biophys; 1998 Mar; 351(2):159-66. PubMed ID: 9514656
[TBL] [Abstract][Full Text] [Related]
3. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase.
Ness GC; Zhao Z; Keller RK
Arch Biochem Biophys; 1994 Jun; 311(2):277-85. PubMed ID: 7911291
[TBL] [Abstract][Full Text] [Related]
4. Farnesol is not the nonsterol regulator mediating degradation of HMG-CoA reductase in rat liver.
Keller RK; Zhao Z; Chambers C; Ness GC
Arch Biochem Biophys; 1996 Apr; 328(2):324-30. PubMed ID: 8645011
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase unmask transcriptional regulation of hepatic low-density lipoprotein receptor gene expression by dietary cholesterol.
Lopez D; Ness GC
Arch Biochem Biophys; 1997 Aug; 344(1):215-9. PubMed ID: 9244400
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of squalene synthase upregulates PCSK9 expression in rat liver.
Bedi M; Niesen M; Lopez D
Arch Biochem Biophys; 2008 Feb; 470(2):116-9. PubMed ID: 18054775
[TBL] [Abstract][Full Text] [Related]
7. Effects of 15-oxa-32-vinyl-lanost-8-ene-3 beta,32 diol on the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase and low density lipoprotein receptor in rat liver.
Ness GC; Lopez D; Chambers CM; Zhao Z; Beach DL; Ko SS; Trzaskos JM
Arch Biochem Biophys; 1998 Sep; 357(2):259-64. PubMed ID: 9735166
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.
Peffley DM; Gayen AK
Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820
[TBL] [Abstract][Full Text] [Related]
9. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
10. Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis.
Kojro E; Füger P; Prinzen C; Kanarek AM; Rat D; Endres K; Fahrenholz F; Postina R
J Alzheimers Dis; 2010; 20(4):1215-31. PubMed ID: 20413873
[TBL] [Abstract][Full Text] [Related]
11. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression by sterols and nonsterols in rat liver.
Ness GC; Eales S; Lopez D; Zhao Z
Arch Biochem Biophys; 1994 Feb; 308(2):420-5. PubMed ID: 8109970
[TBL] [Abstract][Full Text] [Related]
12. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
[TBL] [Abstract][Full Text] [Related]
13. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
14. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
Kocarek TA; Reddy AB
Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
[TBL] [Abstract][Full Text] [Related]
15. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression.
Ness GC; Lopez D; Chambers CM; Newsome WP; Cornelius P; Long CA; Harwood HJ
Biochem Pharmacol; 1998 Jul; 56(1):121-9. PubMed ID: 9698096
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
al Rayyes O; Wallmark A; Florén CH
Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
[TBL] [Abstract][Full Text] [Related]
17. The squalestatins: decarboxy and 4-deoxy analogues as potent squalene synthase inhibitors.
Chan C; Andreotti D; Cox B; Dymock BW; Hutson JL; Keeling SE; McCarthy AD; Procopiou PA; Ross BC; Sareen M; Scicinski JJ; Sharratt PJ; Snowden MA; Watson NS
J Med Chem; 1996 Jan; 39(1):207-16. PubMed ID: 8568810
[TBL] [Abstract][Full Text] [Related]
18. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Mosley ST; Kalinowski SS; Schafer BL; Tanaka RD
J Lipid Res; 1989 Sep; 30(9):1411-20. PubMed ID: 2513368
[TBL] [Abstract][Full Text] [Related]
19. Effect of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on the induction of low-density lipoprotein receptor in HepG2 cells.
Hayashi K; Kurokawa J; Nomura S; Kuga Y; Ohkura Y; Kajiyama G
Biochim Biophys Acta; 1993 Apr; 1167(2):223-5. PubMed ID: 8466953
[TBL] [Abstract][Full Text] [Related]
20. Discovery, biosynthesis, and mechanism of action of the zaragozic acids: potent inhibitors of squalene synthase.
Bergstrom JD; Dufresne C; Bills GF; Nallin-Omstead M; Byrne K
Annu Rev Microbiol; 1995; 49():607-39. PubMed ID: 8561474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
